Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.570 -0.080 (-1.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
News headline image
7 Unknown Biotech Stocks That Could Rocket in 2023 ↗
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline. 
Via InvestorPlace
News headline image
Nikola, Super Micro Computer And Other Big Losers From Monday ↗
U.S. stocks closed higher with the Dow Jones gaining around 197 points on Monday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
News headline image
Twilio, AMTD Digital And Other Big Gainers From Wednesday ↗
U.S. stocks closed mostly higher with the Nasdaq 100 gaining around 100 points on Wednesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
  
Via Benzinga
News headline image
ImmunityBio Expects To Submit US Application For VesAnktiva In Bladder Cancer This Month ↗
ImmunityBio Inc (NASDAQ: IBRX)  
Via Benzinga
News headline image
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday. 
Via Benzinga
News headline image
Why Hill International Is Trading Higher By 15%; Here Are 30 Stocks Moving Premarket ↗
Gainers NewAge, Inc. (NASDAQ: NBEV) shares rose 19.7% to $0.2432 in pre-market trading. NewAge recently received Nasdaq notice on late filing of its form 10-Q. 
Via Benzinga
News headline image
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session ↗
Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 ↗
  
Via Benzinga
News headline image
Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome... 
Via Benzinga
News headline image
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday ↗
Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news. 
Via Benzinga
News headline image
Recap Of Thursday's Biotech Catalysts - End of The Day Summary ↗
 
Via Benzinga
News headline image
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday ↗
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split. 
Via Benzinga
News headline image
FDA Accepts ImmunityBio's Bladder Cancer Candidate For Review ↗
The U.S. Food and Drug Administration (FDA) accepted for review ImmunityBio’s (NASDAQ: IBRX) Biologics License Application (BLA) for its lead asset N-803 in the treatment of patients with... 
Via Benzinga
News headline image
ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
From ImmunityBio
Via Business Wire
News headline image
7 Best Pharmaceutical Stocks to Buy Now ↗
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world. 
Via InvestorPlace
News headline image
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
From ImmunityBio, Inc.
Via Business Wire
News headline image
7 Cheap Biotech Stocks to Buy Now ↗
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
Via InvestorPlace
News headline image
ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From ImmunityBio, Inc.
Via Business Wire
News headline image
99 Biggest Movers From Yesterday ↗
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company. 
Via Benzinga
News headline image
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from... 
Via FinancialNewsMedia
News headline image
ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
From ImmunityBio, Inc.
Via Business Wire
News headline image
Bonds Are Screaming “Recession.” That’s Great News For One Top Sector. ↗
The 10-2 year treasury yield spread is close to zero. Here's what you should do about this warning sign of a coming recession. 
Via InvestorPlace
Development of Novel Innovative Diagnostic tests Generating Huge Revenue Opportunity for Global Blood Testing Market
Palm Beach, FL – February 16, 2022 – FinancialNewsMedia.com News Commentary – The global blood testing market has grown during the pandemic and is expected to continue to rise in the coming years.... 
Via FinancialNewsMedia
News headline image
ImmunityBio's Ankitva Shows 100% Survival At Two Years In Bladder Cancer Setting ↗
ImmunityBio Inc (NASDAQ: IBRX) announced data from its bladder cancer trial (QUILT-3.032) Phase 2/3 study of intravesical BCG plus Anktiva (N-803). The data showed... 
Via Benzinga
News headline image
ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility
From ImmunityBio, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.